Data from three observational databases have suggested that survival in patients with ALS
who take riluzole is far greater than that reported in randomized controlled studies. This …

The development of the disease modifying drug, riluzole, is changing the natural history of
amyotrophic lateral sclerosis (ALS). Let us take the 'classic'ALS patient as portrayed by ALS …

Amyotrophic lateral sclerosis is a fatal CNS neurodegenerative disease. Despite intensive
research, current management of amyotrophic lateral sclerosis remains suboptimal from …

The third International Stroke Trial (IST-3) is the largest (n= 3035) randomised controlled trial
of intravenous alteplase for acute ischaemic stroke to date. 1 Participants in IST-3 were older …

Riluzole is the only therapy proven in clinical trials to prolong amyotrophic lateral sclerosis
(ALS) survival (approximately three months). Questions remain concerning riluzole's …

ON JULY 11, 2007, 1 AUTHORS MITSUMOTO AND Rabkin presented the unusual case of a
patient with amyotrophic lateral sclerosis (ALS) who was a prominent neurologist …

The availability of a drug that provides modest relief in ALS without altering its inevitable
progression and end, has posed new ethical and economic problems for patients …

Graphs show the effects of lithium treatment on disease symptom progression and survival
in patients with ALS (a, b, d, and e) using different scales to measure pulmonary function …

Abstract On July 15, 2021, the FDA asked Amylyx to immediately file a new drug application
(NDA) so they could review the entirety of data on a single study of AMX0035 for people with …

Objective To compare the effect of riluzole on median survival in population studies of
patients with amyotrophic lateral sclerosis (ALS) with that observed in clinical trials …